RxDoctor Payments Data

Osvaldo Mardones, MD

Internal Medicine · Bradenton, FLNPI 1437144524

Payments from drug & device makers

$7,221in general payments, 2019–2025

Across 393 payments — averaging $18.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$895
  • AstraZeneca$767
  • Bayer$670
  • Novartis$445
  • GSK$421
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$7,18199%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,221 in reported general payments places this provider in the 90th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$141,258
Medicare patients
592
Services billed
2,223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide232$239,548
FarxigaDapagliflozin Propanediol179$177,034
JardianceEmpagliflozin104$123,097
EliquisApixaban111$116,158
Trelegy ElliptaFluticasone/Umeclidin/Vilanter165$111,638
MounjaroTirzepatide81$86,542
XareltoRivaroxaban51$56,423
MyrbetriqMirabegron35$36,404
TrulicityDulaglutide33$36,162
Repatha SyringeEvolocumab55$32,794
Repatha SureclickEvolocumab42$31,331
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$29,370
JanuviaSitagliptin Phosphate26$29,248
LinzessLinaclotide32$24,078
Tresiba Flextouch U-100Insulin Degludec32$19,558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,051$239,548232 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$767$212,378237 claims
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$369$148,295135 claims
Lilly USA, LLCMounjaro, Trulicity$895$122,704114 claims
PfizerEliquis$274$116,158111 claims
GSKTrelegy Ellipta$421$111,638165 claims
Johnson & JohnsonXarelto$34$56,42351 claims
Astellas Pharma US IncMyrbetriq$151$36,40435 claims
MerckJanuvia$135$29,24826 claims
AbbVieLinzess$411$24,07832 claims
BayerKerendia$670$12,42716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →